This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland
by Zacks Equity Research
Zacks.com highlights: Colfax, United Therapeutics, Trinseo, Xilinx and Archer Daniels Midland
UTHR vs. NBIX: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. NBIX: Which Stock Is the Better Value Option?
5 Stocks Trading Near 52-Week High With More Upside in Store
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
BioLineRx Stock Up on Stake Increase in Lead Cancer Program
by Zacks Equity Research
BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.
Should Value Investors Pick United Therapeutics (UTHR) Stock?
by Zacks Equity Research
Is United Therapeutics (UTHR) a great pick from the value investor's perspective right now? Read on to know more.
United Therapeutics In-Licenses Rights to IPF Candidate
by Zacks Equity Research
United Therapeutics (UTHR) buys North America rights to early-stage candidate SM04646 from private company Samumed. The candidate is being developed for idiopathic pulmonary fibrosis.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
MannKind Stock Up on Licensing Deal With United Therapeutics
by Zacks Equity Research
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars
by Zacks Equity Research
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
United Therapeutics (UTHR) Up 0.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q2 Earnings Flat Y/Y, Shares Dip
by Zacks Equity Research
United Therapeutics (UTHR) reports unimpressive second-quarter earnings. Sales rise sequentially. Shares sink 5%.
United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 29.76% and 27.27%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for July 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
United Therapeutics (UTHR) Up 3.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
United Therapeutics (UTHR) Q1 Earnings Rise, Sales Drop Q/Q
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share rise in the first quarter. Sales drop sequentially due to unfavorable timing of distributor orders. Shares sink almost 7%.
Why Is United Therapeutics (UTHR) Down 10.7% Since Its Last Earnings Report?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should Value Investors Pick United Therapeutics (UTHR) Stock?
by Zacks Equity Research
United Therapeutics (UTHR) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
United Therapeutics (UTHR) Q4 Earnings Decline on High Costs
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.
United Therapeutics (UTHR) Collaborates With Corsair Pharma
by Zacks Equity Research
United Therapeutics (UTHR) entered into an exclusive license agreement with Corsair Pharma.
United Therapeutics PAH Drug's Exclusivity Period Extended
by Zacks Equity Research
United Therapeutics' PAH drug, Adcirca has been granted six months pediatric exclusivity. This will delay generic competition for the drug for an additional six months.
United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat
by Zacks Equity Research
United Therapeutics' (UTHR) earnings grow year over year in the third quarter of 2017. Revenues too surpass estimates in the reported quarter.
Is United Therapeutics a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now from multiple angles.
J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.
United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top
by Zacks Equity Research
United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.
Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today
by Madeleine Johnson
On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.